Spots Global Cancer Trial Database for Gonadotropin-releasing Hormone Agonist Prior to Myomectomy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Gonadotropin-releasing Hormone Agonist Prior to Myomectomy

Official Title: Phase 3 Study of Experience With a Gonadotropin-releasing Hormone Agonist Prior to Myomectomy - Comparison of 2 Versus 3 Monthly Doses.

Study ID: NCT01581944

Conditions

Fibroids

Interventions

2 Doses Goserelin

3 Doses Goserelin

Study Description

Brief Summary: Fibroids are common in the West Indian population (30-40% of reproductive women).Fibroids are benign growth in the womb or uterus and in order to preserve the fertility of women they, require an operation called myomectomy or shelling out of the fibroid. This procedure can be associated with large blood loss. In current practice some obstetricians use a gonadotropin releasing hormone agonist prior to the operation to reduce blood loss. Gonadotropin releasing hormone agonist is used in current gynaecological practice to treat women with heavy periods. In this study the investigators randomised women to either 2 or 3 doses of the gonadotropin agonist prior to their operation and no treatment. The intraoperative blood loss was measured. The study hypothesis: To determine whether administration of gonadotropin releasing hormone agonist prior to myomectomy reduces intraoperative blood loss.

Detailed Description: Variables noted preoperatively: * Age * Parity * Ethnicity * Ultrasound findings Variables noted intra-operatively: * Size of largest fibroid * Estimated blood loss